SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-18-028299
Filing Date
2018-11-08
Accepted
2018-11-08 08:13:16
Documents
58
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q 9/30/18 ovid-10q_20180930.htm 10-Q 1750129
2 EX-31.1 ovid-ex311_8.htm EX-31.1 21251
3 EX-31.2 ovid-ex312_6.htm EX-31.2 21502
4 EX-32.1 ovid-ex321_7.htm EX-32.1 7559
  Complete submission text file 0001564590-18-028299.txt   5510288

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT ovid-20180930.xml EX-101.INS 1124101
6 XBRL TAXONOMY EXTENSION SCHEMA ovid-20180930.xsd EX-101.SCH 39739
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ovid-20180930_cal.xml EX-101.CAL 31991
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ovid-20180930_def.xml EX-101.DEF 125726
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ovid-20180930_lab.xml EX-101.LAB 292851
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ovid-20180930_pre.xml EX-101.PRE 230848
Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036
Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38085 | Film No.: 181168266
SIC: 2834 Pharmaceutical Preparations